ResultsIQ

ResultsIQ › Latest results › Krsnaa Diagnostics Limited

Krsnaa Diagnostics Limited Q2 FY26 results press release summary

NSE: KRSNAA · BSE: 543328

Results press release of 7 Nov 2025, summarised by AI from the filing.

Management anticipates meaningful revenue contribution from the Rajasthan PPP starting Q4 FY26 and a full-year impact in FY27.

Key takeaways

  1. Rajasthan guidance Management anticipates meaningful revenue contribution from the Rajasthan PPP starting Q4 FY26 and a full-year impact in FY27.
  2. Receivable cycle Receivable cycle around 150+ days, reflecting a temporary transition linked to new central government payment norms.
  3. Volume growth Revenue growth driven by expanding patient volumes and growing confidence in the diagnostic network across India.

Original filing on BSE

Krsnaa Diagnostics Limited Q1 FY27 results

As filed: Revenue ₹236 cr (+22% year on year), EBITDA ₹58.0 cr (+14% year on year), PAT ₹16.6 cr (−21% year on year), EBITDA margin 24.6% (−181 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹193 cr (+4% year on year), EBITDA ₹54.9 cr (+2% year on year), PAT ₹41.7 cr (+99% year on year), EBITDA margin 28.5% (−54 bps). Score 30 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was well above it. EBITDA margin fell 54 bps year on year. Other income 61% of PBT. Revenue rose ₹6.6 cr on a year ago, against ₹20.0 cr the year before. Share price after the results: −2.9% in 30 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹181 cr (+4% year on year), EBITDA ₹46.5 cr (+3% year on year), PAT ₹15.3 cr (−20% year on year), EBITDA margin 25.6% (−8 bps). Score 19 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin was flat year on year. Revenue fell 12% from last quarter. Revenue rose ₹6.2 cr on a year ago, against ₹17.0 cr the year before. Share price after the results: −15.3% in 29 days (Nifty 500: −4.0%).
  • Q2 FY26: Revenue ₹206 cr (+11% year on year), EBITDA ₹60.0 cr (+25% year on year), PAT ₹24.0 cr (+20% year on year), EBITDA margin 29.1% (+332 bps). Score 49 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA growth was in line with it; profit growth was above it. EBITDA margin rose 332 bps year on year. Share price after the results: +3.7% in 28 days (Nifty 500: +1.3%).
  • Q1 FY26: Revenue ₹193 cr (+14% year on year), EBITDA ₹51.0 cr (+21% year on year), PAT ₹21.0 cr (+17% year on year), EBITDA margin 26.4% (+172 bps). Score 47 of 100, In line with trend. Revenue and EBITDA growth were below the company's own trend; profit growth was in line with it. EBITDA margin rose 172 bps year on year. Revenue rose ₹23.0 cr on a year ago, against ₹30.0 cr the year before. Share price after the results: −2.5% in 30 days (Nifty 500: +1.9%).
  • Q4 FY25: Revenue ₹186 cr (+12% year on year), EBITDA ₹54.0 cr (+23% year on year), PAT ₹21.0 cr (+11% year on year), EBITDA margin 29.0% (+253 bps). Score 48 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was below it; profit growth was in line with it. EBITDA margin rose 253 bps year on year. Revenue rose ₹20.0 cr on a year ago, against ₹33.0 cr the year before. Share price after the results: −7.2% in 30 days (Nifty 500: +3.7%).
  • Q3 FY25: Revenue ₹175 cr (+11% year on year), EBITDA ₹45.0 cr (+22% year on year), PAT ₹19.0 cr (+46% year on year), EBITDA margin 25.7% (+230 bps). Score 61 of 100, In line with trend. EBITDA margin rose 230 bps year on year. Other income 36% of PBT. Not enough history for a trend yet: scored on growth alone. Revenue fell 6% from last quarter.
  • Q2 FY25: Revenue ₹179 cr, EBITDA ₹52.0 cr, PAT ₹22.0 cr, EBITDA margin 29.1%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Krsnaa Diagnostics Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.